DCTH vs IDYA: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

IDYA is the larger of the two ($2.51B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 0.08). DCTH is the smaller challenger ($655.23M), expected to make money next year (69.12x forward earnings): more room to run, but more to prove. If you believe in growth, IDYA fits: analysts expect its revenue to rise 181% next year, against 20% for DCTH. If you believe in profit, DCTH fits: it is expected to make money next year (69.12x forward earnings), while IDYA is still expected to post a loss.

DCTH vs IDYA: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricDCTHIDYAWhat it tells you
Market cap$655.23M$2.51BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E69.12-6.11Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.600.08Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range74% of range1% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.902.29How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how DCTH and IDYA affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DCTH and IDYA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DCTH and IDYA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Delcath Systems (DCTH) do?

Delcath Systems, based in New York, develops and sells percutaneous hepatic perfusion (PHP), a procedure that isolates the liver's blood supply, delivers a high dose of the chemotherapy drug melphalan directly to it, and runs the returning blood through filters before it re-enters the body. In the US the product is sold as HEPZATO KIT, approved by the FDA in August 2023 for adults with uveal melanoma (a rare eye cancer) that has spread to the liver and cannot be removed surgically. In Europe the same filtration device is sold as CHEMOSAT. Each HEPZATO treatment is a hospital procedure performed by an interventional radiology and surgical oncology team, so growth depends on how many cancer centers are trained and actively treating patients.

Full DCTH guide

What does IDEAYA Biosciences (IDYA) do?

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) is a clinical-stage precision-medicine oncology company that designs targeted therapies for molecularly defined solid tumors. Its scientific engine is synthetic lethality, an approach that exploits genetic vulnerabilities specific to cancer cells, supported by an in-house DECIPHER CRISPR platform for target and biomarker discovery. The lead asset, darovasertib (IDE196), is a protein kinase C inhibitor being developed for uveal melanoma, a rare and hard-to-treat eye cancer, in both the metastatic setting (with crizotinib, partnered with Servier) and as neoadjuvant and adjuvant therapy for primary disease. Behind it sits a pipeline including IDE397 (MAT2A inhibitor) for MTAP-deleted cancers, IDE892 (PRMT5), IDE849 (a DLL3-targeting topoisomerase-I ADC), IDE161 (PARG), IDE275 (Werner helicase), IDE705 (Pol-theta helicase), IDE574 (KAT6/7) and a newly nominated candidate, IDE101, aimed at CDKN2A-deficient solid tumors.

Full IDYA guide

DCTH vs IDYA: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • DCTH drivers: More treatment centers and more patients per center; Profitability and cash generation.
  • IDYA drivers: Darovasertib approval and launch in uveal melanoma; Synthetic-lethality and precision pipeline breadth.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Delcath sells essentially one product for one rare cancer. For IDYA, as a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news.

DCTH or IDYA: which should you pick?

If the story you believe is DCTH's (More treatment centers and more patients per center), DCTH is the more direct way to own it; if it is IDYA's (Darovasertib approval and launch in uveal melanoma), IDYA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DCTH and IDYA guides.

DCTH vs IDYA: the full fundamentals

DCTH. At about $18.78 a share (November 20, 2026) and roughly 36 million shares including pre-funded warrants, Delcath is valued near $650 million, or about 5.9 times trailing revenue and roughly 5.0 times after netting out cash. Trailing earnings are small, about $6.7 million once the fourth-quarter 2025 loss is included, so the price-to-earnings ratio is very high and swings with each quarter. Guidance of $115 million to $117 million for 2026 implies fourth-quarter revenue of roughly $26 million to $28 million, below the third quarter's $35.1 million, which suggests management is leaving room for uneven volume. Published analyst targets earlier in 2026 ranged from roughly $19 to $30, and the average of five targets tracked by Yahoo Finance is about $28.60.

IDYA. IDEAYA is pre-product-revenue, so traditional multiples like P/E do not apply and the market values it on pipeline probability and cash runway. With ~$1.15 billion of cash and securities against a ~$2.5 billion market cap, close to half the valuation now sits in the balance sheet, and the rest is darovasertib and IDE849 option value; the share price fell faster than the cash balance this quarter. Analysts expect a 2026 loss near ~$4.78 a share, and the mean target of ~$51 sits roughly double the ~$26 price, though RBC cut its target to $45 from $48 on November 4 while Wedbush raised its to $63.

Headline figures (approximate, November 2026): DCTH shows revenue (ttm) ~$110 million, revenue growth (q3 2026, year over year) ~70%, net income (ttm) ~$6.7 million, gross margin (q3 2026) ~89%; IDYA shows revenue (ttm) ~$36.5M of collaboration revenue; Q3 2026 ~$10.2M, down ~95% from the Q3 2025 partnership payment, net income (ttm) ~-$420M; Q3 2026 net loss ~$126M, eps ~-$4.50 trailing; Q3 2026 ~-$1.22 vs ~-$1.16 expected, cash and debt ~$1.15B cash and marketable securities (September 30, 2026); ~$30M debt.

The bottom line: DCTH vs IDYA

DCTH and IDYA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DCTH and IDYA exposure against your real portfolio. It is not an investment adviser.

Wondering how DCTH or IDYA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Delcath Systems

Ask Walnut's AI anything about DCTH and see how it fits what you own.

FAQ

What is the difference between DCTH and IDYA?

+

Delcath Systems, based in New York, develops and sells percutaneous hepatic perfusion (PHP), a procedure that isolates the liver's blood supply, delivers a high dose of the chemotherapy drug melphalan directly to it, and runs the returning blood through filters before it re-enters the body. IDEAYA Biosciences, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is DCTH or IDYA the better stock?

+

Neither is universally better. IDYA is the larger incumbent; DCTH is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, DCTH or IDYA?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both DCTH and IDYA?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of DCTH vs IDYA?

+

DCTH: Delcath sells essentially one product for one rare cancer. Uveal melanoma affects only a few thousand people a year in the US, and only a portion of them develop liver metastases that fit the HEPZATO label, so the current market has a ceiling. Sales are concentrated: two customers accounted for about 31% of revenue in the first nine months of 2026, and a third for about 6.5%, so a slowdown at one large hospital shows up quickly in the numbers. The fourth quarter of 2025 showed how lumpy volume can be, with a net loss of about $1.9 million after a guidance cut that sent the stock sharply lower. The procedure carries serious side effects, including blood count suppression, and the FDA label includes a boxed warning and a restricted distribution program, which limits how fast new sites can start. Competing systemic drugs, such as Immunocore's Kimmtrak and newer targeted agents in development, could change treatment sequencing. The colorectal and breast trials are randomized Phase 2 studies and may not succeed. Pricing and reimbursement, including 340B discounts and the Medicaid rebate agreement, can pressure realized prices. At about 5.9 times trailing sales and roughly 69 times forward earnings estimates, after a gain of about 89% in 2026, the valuation already assumes continued growth. IDYA: As a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. The FDA could delay or decline the darovasertib NDA, or approval could come with a narrow label or slow commercial uptake in a rare indication. Earlier-stage programs (IDE397, IDE849, IDE161 and others) carry high failure rates typical of oncology drug development, and the company notes that FDA feedback from Type C meetings is preliminary and nonbinding. Despite a large cash balance, continued spending and a shelf registration point to future dilution as a likely funding mechanism. The company also faces competition from established and emerging therapies in its target indications, and the stock is historically volatile, as the ~39% slide over the three months to November 20, 2026 showed even through positive regulatory news. Running several registrational programs at once (OptimUM-11 and two planned IDE849 programs) raises the spending rate, and EPS has missed consensus in each of the last three quarters (Q3 2026 ~-$1.22 vs ~-$1.16).

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DCTH or IDYA; figures are approximate and dated (as of November 2026). Verify current data before investing.